Abstract | BACKGROUND: METHODS: We retrospectively analyzed 65 kidney transplant (KT) recipients who received ≥1 dose of influenza vaccine (pandemic or seasonal) during the 2009-2010 campaign. Participants were classified into 2 groups: those who received a squalene-based AS03- or MF59-adjuvanted vaccine ("adjuvanted vaccination" [AV] group, n = 37) and those who exclusively received non-adjuvanted vaccines ("non-adjuvanted vaccination" [NAV] group, n = 28). Primary outcomes included occurrence of biopsy-proven acute graft rejection (BPAR) and graft function at months 6 and 12 after vaccination. Patients were followed up until graft loss, death, or October 2010. RESULTS: Four episodes of BPAR occurred during post-vaccination follow-up, with no differences between the AV and NAV groups, in terms of cumulative incidence (5.4% vs. 7.1%, respectively; P = 0.581), incidence rate (0.22 vs. 0.18 episodes per 1000 transplant-days; P = 0.950), or occurrence of severe episodes (T-cell-mediated BPAR of grade ≥2a) (2.7% vs. 3.6%; P = 0.680). No between-group differences were seen in graft function after vaccination. CONCLUSION: Adjuvanted influenza vaccination in KT recipients seems to be safe regarding graft outcome.
|
Authors | M Fernández-Ruiz, C Lumbreras, M P Arrazola, F López-Medrano, A Andrés, J M Morales, J R de Juanes, J M Aguado |
Journal | Transplant infectious disease : an official journal of the Transplantation Society
(Transpl Infect Dis)
Vol. 17
Issue 2
Pg. 314-21
(Apr 2015)
ISSN: 1399-3062 [Electronic] Denmark |
PMID | 25728936
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Adjuvants, Immunologic
- Immunosuppressive Agents
- Influenza Vaccines
- Squalene
|
Topics |
- Adjuvants, Immunologic
(therapeutic use)
- Adult
- Aged
- Cohort Studies
- Female
- Graft Rejection
(epidemiology, pathology, prevention & control)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Influenza Vaccines
(therapeutic use)
- Influenza, Human
(prevention & control)
- Kidney Failure, Chronic
(surgery)
- Kidney Transplantation
- Male
- Middle Aged
- Prospective Studies
- Retrospective Studies
- Risk Factors
- Squalene
(therapeutic use)
- Transplant Recipients
|